Reports
Sale
Global Vasomotor Symptoms Treatment Market Share, Size, Analysis: By Route of Administration: Oral, Parenteral, Topical; By Type of Therapy: Hormonal Therapies, Non-Hormonal Therapies, Others; By Distribution Channel: Hospital Based Pharmacies, Online Pharmacies, Retail Pharmacies; Regional Analysis; Supplier Landscape; 2024-2032
Global Vasomotor Symptoms Treatment Market Outlook
The vasomotor symptoms treatment market size was estimated to be worth USD 9.40 billion in 2023. Driven by the rise in the number of vasomotor symptoms cases, the market is expected to rise at a CAGR of 6.7% during the forecast period of 2024-2032 to attain a value of more than USD 16.87 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Vasomotor Symptoms: Insights, Causes, Risk Factors, and Treatment
Vasomotor symptoms are the symptoms that occur during menopause due to the constriction of blood vessels. The common vasomotor symptoms include hot flashes, night sweats, and changes in blood pressure.
Vasomotor symptoms occur at menopause because of the substantial hormonal changes that can affect the blood pressure and temperature regulator of the body. The significant estrogen level decrease triggers the nervous system, making the patient restless.
Vasomotor symptoms are more prevalent in African Americans than in Asian Americans. Smoking and obesity further increase the chances of this disorder.
The management of vasomotor symptoms is done using medications. The first-line treatment includes the use of hormonal regulators and anti-depressant drugs. Several lifestyle remedies are also incorporated to manage vasomotor symptoms.
According to the vasomotor symptoms treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Market Breakup by Type of Therapy
- Hormonal Therapies
- Estrogen Replacement Therapies
- Pregestational Therapies
- Non-Hormonal Therapies
- Clonidine
- Serotonin Reuptake Inhibitors
- Gabapentin
- Others
Market Breakup by Distribution Channel
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Vasomotor Symptoms Treatment Market Scenario
The rising prevalence of vasomotor symptoms, such as hot flashes and night sweats during menopausal phases, is anticipated to boost the market growth. According to the International Journal of Applied & Basic Medical Research, nearly 88% of women reported menopausal and vasomotor symptoms, thus facilitating the demand for more therapeutic options.
The increasing investments in the research and development activities by the key players are driving the treatment of the vasomotor symptoms treatment market development. This further contributes to the discovery of novel therapeutic interventions, that will propel the market expansion.
Additional factors, such as a rise in the adoption of a sedentary lifestyle, an increase in the number of mergers and acquisitions, and raising awareness regarding vasomotor symptoms are attributing to the growth of the market.
Regional Insights
North America is anticipated to account for the largest revenue share of the global market. This is due to the high incidence of post-menopausal symptoms, raising awareness about women’s health, and increasing expenditure in the healthcare sector. The significant presence of key global players in this region is also projected to boost the market growth.
During the forecast period, Latin America is expected to witness the fastest growth in the vasomotor symptoms treatment market. The factors leading to this rapid growth include the rising awareness regarding menopausal symptoms and more significant expenditure in the research and development sector.
Therapeutic Landscape
There are several therapeutic interventions for the management of vasomotor symptoms. The procedures used for the treatment of vasomotor symptoms are pharmacological and non-pharmacological. In pharmacological ones, there are two main primary therapies, hormonal replacement therapy (HRT) and non-hormonal medications.
Standard Therapies: Hormonal and Non-Hormonal Therapeutic Interventions
During menopause, there is a substantial reduction in the levels of oestrogen and progesterone. Hormonal replacement therapies are generally utilised to restore reduced hormonal levels, which will subsequently help regulate average body temperature. There are two hormone replacement therapies, oestrogen therapy and oestrogen progesterone hormone therapy.
Hormonal replacement therapies have associated adverse effects; therefore, there is a shift toward non-hormonal medications. Different medications can be incorporated into the treatment regimen depending on the vasomotor symptoms. Serotonin reuptake inhibitors, such as citalopram and fluoxetine, are generally used for hot flashes.
Other medications, such as antidepressants, anti-seizure, urinary, blood pressure, and over-the-counter drugs, also help alleviate vasomotor symptoms.
Alternative treatments, including acupuncture, hypnosis, meditation, and relaxation techniques, have been beneficial for managing menopausal and vasomotor symptoms.
Clinical Trial Landscape
The currently available therapies are associated with several adverse effects and thus leading to several other diseases and comorbidities. Hence, scientists are performing clinical trials for novel therapeutic interventions that will be more effective and have fewer side effects.
Emerging Therapies: Discovery of Novel Medications
M2S Hot Flash Study, an ongoing clinical trial by Fervent Pharmaceuticals, is being performed to manage vasomotor symptoms. This virtual Phase II clinical trial treats moderate night sweats and hot flashes. The primary objective is to analyse the safety and efficacy of peri and post-menopausal therapy.
Astellas Pharma, a key player, is performing a SKYLIGHT 4 clinical trial study to assess the safety and efficacy of fezolinetant, a non-hormonal therapy. Phase III trials are under process for testing the safety and tolerability of this investigational selective neurokinin three receptor antagonist on endometrial health.
Another set of clinical trials is undergoing for the novel neurokinin three receptor antagonist, which is anticipated to provide the potential treatment for managing vasomotor symptoms. Acer Therapeutics is conducting Phase II clinical trials for its ACER-801 (osanetant) drug, and if successfully approved can benefit in the alleviation of vasomotor symptoms.
With the increasing number of key players, there is a rise in the number of drugs under the pipeline. These novel products' approval and launch are expected to boost the market growth.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the vasomotor symptoms treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Bayer AG
- Fervent Pharmaceuticals, LLC
- Astellas Pharma Inc.
- Frazier Healthcare Partners
- Mitsubishi Tanabe Pharma Corporation
- Eli Lilly and Company
- AbbVie Inc.
- AMAG Pharmaceuticals Inc.
- Emcure Pharmaceuticals Limited
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Route of Administration |
|
| Breakup by Type of Therapy |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Vasomotor Symptoms Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Vasomotor Symptoms Treatment Market
8.1 Global Vasomotor Symptoms Treatment Market Overview
8.2 Global Vasomotor Symptoms Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Vasomotor Symptoms Treatment Market Historical Value (2015-2021)
8.2.1.2 Global Vasomotor Symptoms Treatment Market Forecast Value (2022-2030)
8.3 Global Vasomotor Symptoms Treatment Market by Route of Administration
8.3.1 Market Overview
8.3.1.1 Oral
8.3.1.2 Parenteral
8.3.1.2.1 Subcutaneous
8.3.1.2.2 Intravenous
8.3.1.3 Topical
8.4 Global Vasomotor Symptoms Treatment Market by Type of Therapy
8.4.1 Market Overview
8.4.1.1 Hormonal Therapies
8.4.1.1.1 Estrogen Replacement Therapies
8.4.1.1.2 Pregestational Therapies
8.4.1.2 Non-Hormonal Therapies
8.4.1.2.1 Clonidine
8.4.1.2.2 Serotonin Reuptake Inhibitors
8.4.1.2.3 Gabapentin
8.4.1.3 Others
8.5 Global Vasomotor Symptoms Treatment Market by Distribution Channel
8.5.1 Market Overview
8.5.1.1 Hospital Based Pharmacies
8.5.1.2 Online Pharmacies
8.5.1.3 Retail Pharmacies
8.6 Global Vasomotor Symptoms Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Middle East and Africa
8.6.1.5 Latin America
9 North America Vasomotor Symptoms Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Canada
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Vasomotor Symptoms Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Germany
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 France
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Italy
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6 Others
11 Asia Pacific Vasomotor Symptoms Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Japan
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 India
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 ASEAN
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Australia
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
11.7 Others
12 Latin America Vasomotor Symptoms Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Argentina
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Mexico
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 Others
13 Middle East and Africa Vasomotor Symptoms Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 Nigeria
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
13.6 Others
14 Global Vasomotor Symptoms Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Bayer AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Fervent Pharmaceuticals, LLC
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Astellas Pharma Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Frazier Healthcare Partners
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Mitsubishi Tanabe Pharma Corporation
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Eli Lilly and Company
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 AbbVie Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 AMAG Pharmaceuticals Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Emcure Pharmaceuticals Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Merck & Co., Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Novartis AG
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Novo Nordisk A/S
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Pfizer Inc.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Teva Pharmaceutical Industries Ltd.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Global Vasomotor Symptoms Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The vasomotor symptoms treatment market size was estimated to be worth USD 9.40 billion in 2023.
The market is expected to rise at a CAGR of 6.7% during the forecast period of 2024-2032 to attain a value of more than USD 16.87 billion by 2032.
The increasing prevalence of vasomotor symptoms, evolving healthcare infrastructure, and more significant investments in the research and development sector are primarily driving the market growth.
Based on the route of administration, the market can be segmented into oral, parenteral, and topical.
Based on the therapy type, the market is divided into hormonal and non-hormonal therapies, among others.
Based on the distribution channel, the market can be categorised into hospital pharmacies, online pharmacies, and retail pharmacies.
On a regional level, the market has been categorised into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. North America is anticipated to hold the maximum share in the market.
The key companies involved in the market are Bayer AG, Fervent Pharmaceuticals, LLC, Astellas Pharma Inc., Frazier Healthcare Partners, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, AbbVie Inc., AMAG Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., and Teva Pharmaceutical Industries Ltd., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER